首页> 美国卫生研究院文献>Clinical Molecular Pathology >PCR in situ hybridisation detection of HPV 16 in fixed CaSki and fixed SiHa cell lines.
【2h】

PCR in situ hybridisation detection of HPV 16 in fixed CaSki and fixed SiHa cell lines.

机译:固定CaSki和固定SiHa细胞系中HPV 16的PCR原位杂交检测。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

AIMS--To investigate the feasibility of using fixed cells with the polymerase chain reaction (PCR) in situ hybridisation and to investigate possible reasons for reaction failure. METHODS--Fixed SiHa and CaSki cells were used in an experimental model of PCR in situ hybridisation for the detection of low and intermediate copy number viral infection in fixed cells. RESULTS--PCR in situ hybridisation was able to detect one to two copies of human papillomavirus (HPV) 16 in SiHa cells, using small fragment amplicons (120 base pairs), confirming the high detection sensitivity and flexibility of the technique. Problems were encountered with localisation of PCR amplified product in CaSki cells (200-300 copies of HPV 16 per cell) owing to diffusion of product post amplification. Overall, 40% of reactions were successful, which confirms the current unreliability of the technique. Within cell preparations, about 50% of cells contained amplified product. CONCLUSION--PCR in situ hybridisation represents the marriage of two revolutionary molecular pathological techniques. However, it is currently unreliable, with reaction failure common. Standardised, dedicated equipment is urgently required if the technique is to achieve universal acceptance. In the future, the technique may be used to detect chromosomal translocations in human tumours and to study cellular gene expression.
机译:目的-研究使用固定细胞进行聚合酶链反应(PCR)原位杂交的可行性,并研究反应失败的可能原因。方法-将固定的SiHa和CaSki细胞用于PCR原位杂交的实验模型中,以检测固定细胞中的低拷贝数和中等拷贝数病毒感染。结果-PCR原位杂交能够使用小片段扩增子(120个碱基对)在SiHa细胞中检测到一到两个拷贝的人乳头瘤病毒(HPV)16,证实了该技术的高检测灵敏度和灵活性。由于扩增后产物的扩散,CaSki细胞中PCR扩增产物的定位遇到了问题(每细胞200-300个HPV 16拷贝)。总体而言,成功进行了40%的反应,这证实了该技术当前的不可靠性。在细胞制备物中,约50%的细胞含有扩增产物。结论-PCR原位杂交代表了两种革命性分子病理技术的结合。然而,它目前不可靠,反应失败很普遍。如果该技术要获得普遍认可,则迫切需要标准化的专用设备。将来,该技术可用于检测人类肿瘤中的染色体易位并研究细胞基因表达。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号